MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2012.11.015

Медицинская библиотека · Journal of the American College of Cardiology · 2012

Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.

Park Kyung Woo, Lee Joo Myung, Kang Si-Hyuck, Ahn Hyo-Suk, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Koo Bon-Kwon, Cho Janghyun, Gwon Hyeon-Cheol, Lee Sung Yoon, Chae In-Ho, Youn Tae-Jin, Chae Jei Keon, Han Kyoo-Rok, Yu Cheol Woong, Kim Hyo-Soo

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to compare the safety and efficacy of the Xience V/Promus everolimus-eluting stent (EES) (Abbott Vascular, Temecula, California) with the Endeavor Resolute zotarolimus-eluting stent (ZES-R) (Medtronic Cardiovascular, Santa Rosa, California) in "all-comer" cohorts.

BACKGROUND

Only 2 randomized controlled trials have compared these stents.

METHODS

The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) and RESOLUTE-Korea registries prospectively enrolled 3,056 patients treated with the EES and 1,998 patients treated with the ZES-R, respectively, without exclusions. Stent-related composite outcomes (target lesion failure [TLF]) and patient-related composite outcomes were compared in crude and propensity score-matched analyses.

RESULTS

Of 5,054 patients, 3,830 (75.8%) had off-label indication (2,217 treated with EES and 1,613 treated with ZES-R). The stent-related outcome (82 [2.7%] vs. 58 [2.9%], p = 0.662) and the patient-related outcome (225 [7.4%] vs. 153 [7.7%], p = 0.702) did not differ between EES and ZES-R, respectively, at 1 year, which was corroborated by similar results from the propensity score-matched cohort. The rate of definite or probable stent thrombosis (18 [0.6%] vs. 7 [0.4%], p = 0.306) also was similar. In multivariate analysis, off-label indication was the strongest predictor of TLF (adjusted hazard ratio: 2.882; 95% confidence interval: 1.226 to 6.779; p = 0.015).

CONCLUSIONS

In this robust real-world registry with unrestricted use of EES and ZES-R, both stents showed comparable safety and efficacy at 1-year follow-up. Overall incidences of TLF and definite stent thrombosis were low, even in the patients with off-label indication, suggesting excellent safety and efficacy of both types of second-generation drug-eluting stents.

Для цитирования: Park Kyung Woo, Lee Joo Myung, Kang Si-Hyuck, Ahn Hyo-Suk, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Koo Bon-Kwon, Cho Janghyun, Gwon Hyeon-Cheol, Lee Sung Yoon, Chae In-Ho, Youn Tae-Jin, Chae Jei Keon, Han Kyoo-Rok, Yu Cheol Woong, Kim Hyo-Soo. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.. Journal of the American College of Cardiology. 2012. DOI: 10.1016/j.jacc.2012.11.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.